

Oryzon to present at upcoming international conferences

- ❖ **HC Wainwright Global Life Sciences Conference - 2018, Monaco**
- ❖ **AACR Annual Meeting 2018, Chicago, Illinois, United States**
- ❖ **13th edition of the European Smallcap Event, Paris, France**

MADRID, SPAIN and CAMBRIDGE, MA, 9 April 2018 – Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced today that Executive Directors of the company will present at several international reputed conferences.

Dr. Tamara Maes, Oryzon's VicePresident and CSO, will present additional preclinical data of ORY-1001 at the AACR Annual Meeting 2018 to be held 14-18 April at the McCormick Place North/South, Chicago, Illinois, USA. See more info at <http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=136>

Dr. Carlos Buesa, Oryzon's CEO will present the recent progresses of ORY-2001 at the HC Wainwright Global Life Sciences Conference - 2018, to be held at Le Meridien Beach Plaza Hotel, Monte Carlo April 8-10. The Company presentation will take place on Tuesday, Apr 10 at 11:05-11:30 AM in Salon Atlantic-W (2nd Floor).

In addition, Dr. Buesa will present the recent progresses of the company at the 13th edition of the European Smallcap Event to be held in Paris on April 16&17 at The Westin Paris – Vendôme Hotel.

The company has recently reported that ORY-2001 has been approved to start its second Phase IIa clinical trial, this time in mild to moderate Alzheimer's patients. ORY-2001 exerts a holistic action in the different alterations seen in patients with AD and other neurodegenerative disorders. Different experiments suggest that ORY-2001 may act as a disease modifying drug. In AD patients and other neurodegenerative disorders, cognitive deterioration is often accompanied by episodes of agitation, aggression, psychosis, apathy and depression. In preclinical studies, ORY-2001 not only restores memory but reduces the exacerbated aggressiveness of SAMP8 mice, a model for accelerated aging and Alzheimer's disease, to normal levels and also reduces social avoidance in rat models maintained in isolation. The drug has been tested in 6 month rat and 9 month dog GLP toxicology studies to enable long term Phase II studies. The safety and tolerability of ORY-2001 has been studied in a Phase I clinical trial with 106 young and elderly healthy volunteers, confirmed LSD1 target engagement and ORY-2001 brain penetration, and allowed to establish the doses for the Phase II dose finding studies in patients. The company recently started a Phase IIa with ORY-2001 in patients with multiple sclerosis which is currently progressing after the FPI was enrolled in January.

ORY-2001 is an orally administered, brain penetrant drug that selectively inhibits LSD1 and MAOB. The molecule acts on several levels, reduces cognitive impairment, memory loss and neuroinflammation, and at the same time exerts neuroprotective effects. In several preclinical models of MS, ORY-2001 exhibits strong and durable efficacy. LSD1 is an epigenetic modulator, which regulates histone methylation and modulates gene expression patterns. Epigenetic approaches to modify the progression of various neurodegenerative

diseases, which focus on the production of changes in gene expression patterns in brain cells, have generated interest in the pharmaceutical industry.

About Oryzon

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field. Oryzon's LSD1 program has resulted in + 20 patent families and has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon's strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case by-case basis to either keep the development in-house or to partner or outlicense the compound for late stage development and commercialization. The company has offices in Spain and USA. For more information, visit www.oryzon.com.

FORWARD-LOOKING STATEMENTS

This communication contains forward-looking information and statements about Oryzon Genomics, S.A., including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates" and similar expressions. Although Oryzon Genomics, S.A. believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon Genomics, S.A. shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon Genomics, S.A., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon Genomics, S.A. to the *Comisión Nacional del Mercado de Valores*, which are accessible to the public. Forward-looking statements are not guarantees of future performance. The auditors of Oryzon Genomics, S.A. have not reviewed them. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon Genomics, S.A. or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon Genomics, S.A. on the date hereof. Except as required by applicable law, Oryzon Genomics, S.A. does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States. The Company's securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of the Company's securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company or the selling security holder, as applicable, that will contain detailed information about the Company and management, as well as financial statements.

US Contact:
The Trout Group
Thomas Hoffmann
+1 646 378 2932
thoffmann@troutgroup.com

Spain:
ATREVIA
Patricia Cobo/Luis Rejano
+34 91 564 07 25
pcobo@atrevia.com
lrejano@atrevia.com

The Company:
Emili Torrell
BD Director
+34 93 515 13 13
etorrell@oryzon.com